Dr Reddy’s Laboratories has received the Drug Identification Numbers (DINs) for Semaglutide Injection from Health Canada as part of the consideration for its approval.
“We continue to engage constructively with the regulatory authority and remain committed to bringing the product to the Canadian market upon approval,’’ the company informed the Bombay Stock Exchange on Friday.
After gaining 10 percent on the reports related to Candian approval for the generic on Thursday, Dr Reddy’s scrip lost 1.73 percent after opening up of trade on Friday and is trading at Rs 1310.05.
Last month, Hyderabad-based Dr Reddy’s launched its injectable semaglutide under the brand name Obeda for the management of type 2 diabetes in the Indian market.
The Dr Reddy’s was the first Indian company to receive Drugs Controller General of India (DCGI) approval for generic semaglutide and made the first-day entry into the segment upon patent expiry.